Meeting
2022 ASCO Annual Meeting
A randomized phase II study of anlotinib combined with STUPP versus STUPP alone in patients with newly diagnosed glioblastoma (GBM).
Authors
Yuan yuan Yuan Chen
Sun Yat-Sen University Cancer Center, Guangzhou, China
Yuan yuan Yuan Chen , Baiqiang Dong , Zhongping Chen
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr TPS2079)
DOI
10.1200/JCO.2022.40.16_suppl.TPS2079
Abstract #
TPS2079
Poster Bd #
414a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).
First Author: Peijing Li
Poster
2014 ASCO Annual Meeting
Survival and quality of life in the randomized, multicenter GLARIUS trial investigating bevacizumab/irinotecan versus standard temozolomide in newly diagnosed, MGMT-non-methylated glioblastoma patients.
First Author: Ulrich Herrlinger
Poster
2022 ASCO Annual Meeting
Bortezomib sensitization of recurrent glioblastoma with unmethylated MGMT promoter to temozolomide, a phase II study (NCT03643549).
First Author: Dorota Goplen
Poster
2022 ASCO Annual Meeting
Phase 2 study to evaluate palbociclib in combination with irinotecan and temozolomide in pediatric patients with recurrent or refractory Ewing sarcoma.
First Author: Theodore Willis Laetsch